Suanfarma Suanfarma

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find the latest Drugs in Development and Pipeline Prospector News of TerThera.

    Client Virtual Booth

    TERTHERA

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Send me more info on How To Grow My Bussiness Digitally?
    TerThera
    Netherlands1 Flag
    Country
    Country
    Netherlands
    Address
    Address
    Minervum 7070 4817 ZK Breda
    Telephone
    Telephone
    +31 (0)76-8200970
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.terthera.com/
    Linkedin
    Linkedin
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Full View ScreenFull Screen View
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Radiopharm Theranostics Expands Supply Agreement with TerThera for Terbium-161 Isotope Use in Prostate Cancer

    Details:

    Under the agreement, TerThera will supply Radiopharm with Terbium-161 and Tb-161 isotope will be linked to a proprietary mAb to form RAD 402, a radiotherapeutic that is being developed by Radiopharm to target KLK3 expression in patients with advanced prostate cancer.


    Lead Product(s): RAD 402,Terbium-161

    Therapeutic Area: Oncology Product Name: RAD 402

    Highest Development Status: PreclinicalProduct Type: Large molecule

    Partner/Sponsor/Collaborator: Radiopharm Theranostics

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Agreement August 24, 2023

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Radiopharm Theranostics Enters Into Supply Agreement with TerThera for Terbium-161 Isotope

    Details:

    The agreement aims to supply Tb-161 for RAD 602, a radiotherapeutic that is being developed by Radiopharm to target protein tyrosine phosphatase mu (PTPmu or PTPμ) for treatment of brain cancers.


    Lead Product(s): RAD602

    Therapeutic Area: Oncology Product Name: RAD602

    Highest Development Status: PreclinicalProduct Type: Small molecule

    Partner/Sponsor/Collaborator: Radiopharm Theranostics

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Agreement April 17, 2023

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    fermion-oy-2024-05-13

    Access Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search